Regeneron offers you biotech gains

Article Excerpt

We think the drug industry will enjoy great success over the next decade. Still, due to the nature of the business, results will vary widely and unpredictably from one drug company to another. A volatile market like the one we expect for drug stocks will include winners and losers. Here’s one we expect to be among the big winners. This stock is a Power Buy. REGENERON PHARMACEUTICALS INC., $719.62, is a buy. Your shares (Nasdaq symbol REGN; TSINetwork Rating: Average) (www.regeneron.com; Shares outstanding: 106.7 million; Market cap: $77.7 billion; No dividends paid) let you tap this leading inventor, developer and producer of a range of medicines for the treatment of serious and debilitating conditions. They include eye disease, cancer and rare inflammatory conditions. The company was founded in 1988 and is headquartered in Tarrytown, New York. It currently has manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. Regeneron has eight FDA-approved medicines, all of which it developed in its own laboratories. The best-selling of the bunch is Eylea. It’s…